ClinicalTrials.gg
Drug

Vedolizumab clinical trials

Also written Entyvio, MLN0002 and LDP-02.

studies test it
91
open now
20
in phase 3
27
first study started
2000

How each study uses vedolizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the vedolizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
20 May 2014 · ENTYVIO · BLA 125476 (FDA, Drugs@FDA)
European Union
22 May 2014 · Entyvio · EMEA/H/C/002782 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Vedolizumab
62
KYNTELES
13
Vedolizumab IV
9
Vedolizumab SC
9
Vedolizumab Injection
3

Brand

Entyvio
43

Development codes

MLN0002
31
LDP-02
10
MLN02
9
MLN0002SC
3

Studies by the year they started

91 studies that test it; most in 2017 (13)

Studies that test vedolizumab, by start year
YearStudies
20001
20072
20081
20092
20101
20111
20145
20155
201611
201713
201811
20195
20203
20217
20224
20234
20247
20257
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
14
Phase 2
20
Phase 3
27
Phase 4
29
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 52 · Other 39

Takeda (41) · Millennium Pharmaceuticals, Inc. (10) · M.D. Anderson Cancer Center (2) · Alimentiv Inc. (2) · ANRS, Emerging Infectious Diseases (2) · Geert D'Haens (2) · Centre Hospitalier Universitaire de Saint Etienne (2) · Massachusetts General Hospital (1)

Often tested with

Tested in the same studies.

Infliximab (4) · Adalimumab (2) · Cyclophosphamide (2) · Tofacitinib (1) · Risankizumab (1) · Mirikizumab (1) · Ustekinumab (1) · Methotrexate (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 8, 4 in phase 3

Studies that test vedolizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses vedolizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 91

See all 91 studies that test vedolizumab →

Given beside what is tested · 8 — vedolizumab is usual care or a partner of the new treatment
As the comparator · 5 — what is tested is compared with vedolizumab

Codes

What other systems call vedolizumab · ClinicalTrials.gg INT005492

  • MeSH (NLM) C543529vedolizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 9RV78Q2002VEDOLIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1538097Confirmed FDA, Wikidata
  • Wikidata Q7918002vedolizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C95798VedolizumabOne source FDA
  • DrugBank DB09033One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.